[Abstract] [Full Text HTML] [Full Text PDF] (in Japanese / 396KB) [Members Only]

J.Jpn. Surg. Soc.. 118(6): 622-627, 2017


Feature topic

ANTI-HER2 TARGETED THERAPY AND HER2-POSITIVE BREAST CANCER SURGERY

Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Isehara, Japan

Yutaka Tokuda

According to Japanese Breast Cancer Registry data, among more than 250,000 patients from 2004 through 2011, HER2-positive primary cases comprised 12.3-15.5% of the total. The 2004 Annual Prognosis Analysis Report revealed that triple-negative breast cancer had the poorest prognosis and was an HER2-positive subtype. In the Japanese guidelines, postoperative adjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancer is recommended. The same long-term effects have been shown for standard chemotherapy if applied either in the preoperative or postoperative setting. Therefore, for HER2-positive breast cancer, preoperative anti-HER2 therapy is recommended. A pathological complete response (pCR) to preoperative therapy has a prognostic impact, especially in HER2-positive breast cancer. Preoperative chemotherapy aimed at achieving pCR combined with trastuzumab and pertuzumab is the currently recommended anti-HER2 therapy.


<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.